Blocking Thbs1 with a genetic approach in triple-negative breast cancer (TNBC) was shown to increase CD8 T cells infiltration/proliferation and improve response to αPD-L1 immunotherapy in mice51. This evidence concerns the gene CD8A and triple-negative breast carcinoma.